Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab maintenance after platinum-based chemotherapy for advanced or metastatic penile squamous cell carcinoma
2018-001427-38Phase 2Active
- Sponsor
- CHU de Besançon
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in penile squamous cell carcinoma (PSCC), sponsored by CHU de Besançon. Primary endpoint: Progression-free survival by RECIST 1.1. Started May 2018; status: active.
02
Drugs
avelumab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on 2018-001427-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001427-38.